The AVIPure-COV2S resin is based on an affinity ligand that is highly selective to the receptor-binding domain within the SARS-CoV-2 spike protein. The resin's selectivity for the receptor-binding domain has been successfully tested with a variety of recombinant protein COVID-19 vaccine constructs, including large trimeric spike proteins, smaller S1 proteins, and other biologics that leverage the receptor-binding domain, according to the company.

"Our resin in particular has several defining characteristics such as high binding capacities and purity, high yields at soft elution conditions, and extended resin stability in sodium hydroxide which makes this product an optimal choice for bioprocess and research applications," said Warren Kett, PhD, chief scientific officer of Avitide.

Presales of the AVIPure-COV2S resin began this month. Commercial quantities will be available for supply in April 2021 for use in good manufacturing practice (GMP) manufacturing operations, the firm said.

Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...